Current Illinois CancerCare Clinical Trals

Leukemia


EA9213 (JIT)

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute
Lymphoblastic Leukemia (T-ALL)


Search Again